By Melissa Lipman ( March 13, 2015, 4:44 PM EDT) -- When the Second Circuit hears arguments next month over whether Actavis PLC should be allowed to pull the older version of Namenda off the shelves before generic-drug competitors can enter the market in July, it will become the first appellate court to take on the issue....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.